BioFirst got license and patent. Stock raised 13 dollars in three days

medical factory BioFirst got another good news! In addition to getting the favor from European ophthalmic factory and signed a license letter of intent, the patent of BioFirst had approved in Korea. It had risen up the stock and from the bottom 40.49 to the highest point 53.49 this week, it gone up to 13 dollars in 3 days. BioFirst signed a license letter of intent with European ophthalmic factory and positively arranges European market. After this, BioFirst got other good news. The patent of “Vitreous Substitute” had approved in the U.S., Taiwan and Australia.it also got the notice from The Korean Intellectual Property Office and had approved in Korea. The expiration date of patent is 2030.
BioFirst mentioned that the technique of Vitreous Substitute was the gelation product, which first used in the renal detachment recovery operations, its innovation leads the whole world. The patents had approved in the U.S., Australia, Taiwan and Korea, and still have under reviewed cases in 10 more countries through PCT. It is an indicative with positive meaning. According to the marketing report, the marketing potential “Vitreous Substitute” can be predicted up to 2 billion dollars per year. BioFirst got the global exclusive license from NHRI, which protected monopolistic global market. BioFirst had submitted a conduction project to the Ministry of Science and Technology and conduct a production factory of Vitreous Substitute in Hsinchu Biomedical Science Park. BioFirst also will get the authentication of GMP and supply the global market.